SEC Form 4 · accession 0001203311-18-000093
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Nov 8, 2018
Accepted (ET)
Nov 9, 2018 · 5:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 8, 2018 | M | 6,670 | $12.16 | A | 739,283 | D | |
| Common StockF3,F1 | Nov 8, 2018 | S | 6,670 | $62.04 | D | 732,613 | D | |
| Common StockF1 | Nov 8, 2018 | M | 13,478 | $12.16 | A | 746,091 | D | |
| Common StockF4,F1 | Nov 8, 2018 | S | 13,478 | $61.29 | D | 732,613 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $12.16 | Nov 8, 2018 | M | 6,670 | D | — | Aug 25, 2019 | Common Stock | 6,670 | 194,811 | D |
| Non-Qualified Stock Option (right to buy)F5 | $12.16 | Nov 8, 2018 | M | 13,478 | D | — | Aug 25, 2019 | Common Stock | 13,478 | 181,333 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $61.76 to $62.37. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $60.74 to $61.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 8/25/10 and monthly thereafter until all the shares were fully vested on 8/25/13.